Alladapt Immunotherapeutics

Oral Food Allergy Immunotherapies

Alladapt Immunotherapeutics is identifying mechanisms to treat food allergies. Food allergy is a disease of the immune system that can be triggered by a range of common foods. For tens of millions of people, this immune response to certain foods is harmful, with potentially life-threatening consequences. As the underlying biology of food allergies grows, Alladapt is using these findings to develop a single therapeutic to support the management of a broad range of common food allergies. Alladapt’s lead drug candidate, ADP101, is being developed for the mitigation of food allergy provoked by either a single or multiple proteins from a wide range of foods. Alladapt hopes to formulate ADP101 as an oral prescription therapy that delivers highly consistent alleviation of allergies to patients.